GenTel® BioSurfaces, Inc. and Van Andel Institute Announce New Technology to Improve Early Detection and Prognosis of Cancer

MADISON, Wis.--(BUSINESS WIRE)--Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute (VARI), a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.